A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.

Research output: Contribution to journalMeeting AbstractAcademic

Original languageEnglish
JournalJournal of Clinical Oncology
Volume35
DOIs
Publication statusPublished - 20 May 2017

Cite this

@article{e10a9ed152034293bf13a5e3abd95bdc,
title = "A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.",
author = "Maria Rovithi and Marlette Labots and Richard and Honeywell and {Ten Tije}, {Albert J.} and Rita Ruijter and Mikkjal Skardhamar and Peters, {Godefridus J.} and Jens Voortman and Verheul, {Henk M. W.}",
year = "2017",
month = "5",
day = "20",
doi = "10.1200/JCO.2017.35.15_suppl.2591",
language = "English",
volume = "35",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",

}

TY - JOUR

T1 - A phase 1/2 study of intermittent, high dose sunitinib in patients with advanced solid tumors.

AU - Rovithi, Maria

AU - Labots, Marlette

AU - Richard,

AU - Honeywell, null

AU - Ten Tije, Albert J.

AU - Ruijter, Rita

AU - Skardhamar, Mikkjal

AU - Peters, Godefridus J.

AU - Voortman, Jens

AU - Verheul, Henk M. W.

PY - 2017/5/20

Y1 - 2017/5/20

U2 - 10.1200/JCO.2017.35.15_suppl.2591

DO - 10.1200/JCO.2017.35.15_suppl.2591

M3 - Meeting Abstract

VL - 35

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

ER -